Market news

Tipranks Press Release.

Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an intervie

Clene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026Clene announces...

Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration. President and CEO Rob Etherington said the co